Sat Feb 01 20:20:00 UTC 2025: **Billionaire Investor Shifts Focus from AI Chips to Weight-Loss Drugs**
**New York, NY** – Philippe Laffont, founder of Coatue Management, a firm managing $26.9 billion in assets, has made a significant portfolio adjustment, reducing his holdings in AI chip giants Nvidia and AMD while significantly increasing investments in weight-loss drug manufacturers Eli Lilly and Novo Nordisk.
Laffont, known for his tech-focused investments, acknowledged the continued potential of Nvidia and AMD, reducing his positions by 26% and 32% respectively. However, he cites the burgeoning weight-loss drug market, projected to reach $100-$130 billion by 2030, as a compelling driver for his increased investment in Eli Lilly and Novo Nordisk. His holdings in Lilly increased by over 19%, and his Novo Nordisk position saw an over 800% boost.
The move reflects Laffont’s strategy of identifying high-growth sectors fueled by innovation. While the tech sector remains a significant part of his portfolio, this shift highlights his diversification into the rapidly expanding pharmaceutical market, driven by the immense success of weight-loss drugs like Mounjaro, Wegovy, Ozempic, and Zepbound. The increasing Medicare coverage for these drugs, particularly for conditions beyond weight loss, further strengthens the market outlook. Analysts suggest Laffont’s move could prove a shrewd investment for the coming years.
First Piper 